Literature DB >> 2200748

Response of monkeys to vaccination with recombinant vaccinia virus which coexpress HIV gp160 and human interleukin-2.

J Ruby1, C Brinkman, S Jones, I Ramshaw.   

Abstract

Immunization of two macaque monkeys with recombinant vaccinia viruses encoding the env gene of HIV-1 (VV-gp160) resulted in demonstrable levels of gp160, gp120 and gp41-specific immunoglobulins in both animals. The virus used to immunize one of the monkeys additionally expressed the human IL-2 gene, which encoded human IL-2 (VV-gp160-IL-2). No toxic side-effects of vaccine-delivered IL-2 were observed. Despite marked attenuation of virulence by the coexpressed lymphokine, the levels of vector-specific antibodies in both animals were similar. Some differences in the HIV-specific reactivity patterns were detected. Serum reactivity of monkey #A56 (VV-gp160) was directed against gp41, whereas monkey #B58 (VV-gp160-IL-2) showed a wider range of recognition, with higher antibody titres against the HIV lysate preparation. Furthermore, this study demonstrates the capacity to boost antibody responses to the vector and coexpressed HIV antigens in primates which are already immune.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2200748     DOI: 10.1038/icb.1990.16

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  4 in total

1.  Smallpox vaccine with integrated IL-15 demonstrates enhanced in vivo viral clearance in immunodeficient mice and confers long term protection against a lethal monkeypox challenge in cynomolgus monkeys.

Authors:  Rafal J Zielinski; Jeremy V Smedley; Pin-Yu Perera; Peter M Silvera; Thomas A Waldmann; Jacek Capala; Liyanage P Perera
Journal:  Vaccine       Date:  2010-08-20       Impact factor: 3.641

Review 2.  Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety.

Authors:  B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

3.  Intranasal administration of human immunodeficiency virus type-1 (HIV-1) DNA vaccine with interleukin-2 expression plasmid enhances cell-mediated immunity against HIV-1.

Authors:  K Q Xin; K Hamajima; S Sasaki; A Honsho; T Tsuji; N Ishii; X R Cao; Y Lu; J Fukushima; P Shapshak; S Kawamoto; K Okuda
Journal:  Immunology       Date:  1998-07       Impact factor: 7.397

4.  IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases.

Authors:  V Bronte; K Tsung; J B Rao; P W Chen; M Wang; S A Rosenberg; N P Restifo
Journal:  J Immunol       Date:  1995-05-15       Impact factor: 5.422

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.